Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Organization Activities
BIONET Corp. was first established in 1999 as the pioneer company in the field of stem cell application in Taiwan as well as in Asia. BIONET has focused: “Stem Cell Therapy” and “Genetic Testing”. In 2007, BIONET completed initial public offering (TPO: 1784) and became the first publicly traded company in the stem cell and genetic industry of Taiwan. Furthermore, in 2012, Genesis Genetics Asia Corp. (GGA), a subsidiary of BIONET, made its IPO (TPO: 4160) as Taiwan’s first public company specialized in both genetic testing and scientific informatics. BIONET is the largest enterprise that the penetration rate is up to 50% for cell therapy and genetic engineering industry in Taiwan.
Contact Information
Address: No.28, 36 Ln., Xinhu 1st Rd.,
Neihu Dist., Taipei City 11494
Taiwan
Phone: +886-2-2795-1777, Monday to Friday, 9am-6pm CST (UTC+8)
Toll-free: 0800-800-018
Email: service@babybanks.com
Website: www.babybanks.com
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Lee-Cheng (L-C) Liu, President and CEO of EirGenix, one of Taiwan’s fastest growing companies in the biotech field, documents the progress made in the set-up of EirGenix’s new commercial biomanufacturing…
Jui-Lin Chen, CEO of MiCareo, provides insights into the development of MiSelect, Micareo’s pioneering platform for the analysis of Circulating Tumor Cells (CTC) and other rare cells, which proudly stands…
Chen Min-Che, founder and managing director of Asclepiumm, provides insights into the main milestones reached and the new partnership opportunities considered by this exciting biotech company, whose Antibody Switch-on Cytotoxicity…
Freddie Höglund, CEO of the European Chamber of Commerce Taiwan (ECCT), and Mike Exton, Managing Director of Novartis Taiwan and Co-Chair of the Pharmaceutical Committee of the ECCT, document the…
Mike Exton, Managing Director at Novartis Taiwan, describes the affiliate’s plans to increase collaboration with the government in order to provide Taiwanese patients with a greater access to innovative, life-changing…
Petar Vazharov, Alvogen’s executive vice president for Asia Pacific, and, Jefferson Wang, general manager of Lotus, provide insights into Lotus’ tremendous evolution from a local generics company into a regional…
The Chairman & CEO of TaiGen Biotechnology discusses the growth opportunities that the company holds in China, its main target market, and documents how her long-term strategic outlook made the…
Yung Fa Chen, ScinoPharm’s President and CEO, documents his strategy to drive the Taiwan-based global success story to new heights, having established itself as an indisputable leader in the API…
JCP is home to over five decades of generic medication production and is a cornerstone household brand for numerous products in Taiwan’s domestic market, most notably with CNS medications. The…
Fangchen Lee, Chairman of YungShin Global Holding on strengthening the groups’s vertical integration, expanding product portfolio, and instilling a collaborative approach in the local generics industry, with the vision to build a Taiwan-based pharmaceutical…
Hong-Jen Chang, former Deputy Minister of Health and current CEO and Chairman of the YFY Biotech Management Company, a Taiwan-based VC fund which has been playing an instrumental role in…
George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech…
See our Cookie Privacy Policy Here
